DK4096717T3 - Behandling af cancer - Google Patents
Behandling af cancer Download PDFInfo
- Publication number
- DK4096717T3 DK4096717T3 DK21702624.4T DK21702624T DK4096717T3 DK 4096717 T3 DK4096717 T3 DK 4096717T3 DK 21702624 T DK21702624 T DK 21702624T DK 4096717 T3 DK4096717 T3 DK 4096717T3
- Authority
- DK
- Denmark
- Prior art keywords
- cancer treatment
- cancer
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062968175P | 2020-01-31 | 2020-01-31 | |
| PCT/EP2021/051938 WO2021151984A1 (en) | 2020-01-31 | 2021-01-28 | Treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4096717T3 true DK4096717T3 (da) | 2025-03-03 |
Family
ID=74494891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21702624.4T DK4096717T3 (da) | 2020-01-31 | 2021-01-28 | Behandling af cancer |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12594343B2 (da) |
| EP (2) | EP4096717B1 (da) |
| JP (2) | JP7682553B2 (da) |
| CN (1) | CN114845740B (da) |
| AU (2) | AU2021213421B2 (da) |
| CA (1) | CA3160557A1 (da) |
| DK (1) | DK4096717T3 (da) |
| ES (1) | ES3014740T3 (da) |
| WO (1) | WO2021151984A1 (da) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114845740B (zh) * | 2020-01-31 | 2026-06-02 | 先天制药公司 | 癌症的治疗 |
| JP7904824B2 (ja) * | 2020-09-15 | 2026-08-13 | シンアフィックス ビー．ブイ． | 抗体－エクサテカンコンジュゲート |
| JP2024501121A (ja) * | 2020-11-25 | 2024-01-11 | イナート・ファルマ・ソシエテ・アノニム | 癌の処置 |
| MX2023011563A (es) * | 2021-03-31 | 2024-02-08 | Emergence Therapeutics Gmbh | Conjugados de anticuerpo anti-nectina-4 y exatecano. |
| EP4086284A1 (en) * | 2021-05-07 | 2022-11-09 | Emergence Therapeutics AG | Anti-nectin-4 antibody exatecan conjugates |
| CN117500528A (zh) * | 2021-06-18 | 2024-02-02 | 北京海步医药科技有限公司 | 连接子及其缀合物 |
| MX2024008036A (es) * | 2021-12-28 | 2024-07-15 | Beigene Switzerland Gmbh | Conjugados de anticuerpo y farmaco. |
| US20250205353A1 (en) * | 2022-03-23 | 2025-06-26 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing nectin-4 |
| CA3248038A1 (en) | 2022-04-12 | 2023-10-19 | Minerva Biotechnologies Corporation | ANTI-MUC1* VARIABLE ANTIBODIES AND RELATED USES |
| WO2023227660A1 (en) * | 2022-05-25 | 2023-11-30 | Innate Pharma | Nectin-4 binding agents |
| EP4285935A1 (en) * | 2022-06-03 | 2023-12-06 | Emergence Therapeutics AG | Novel anti-nectin-4 antibody camptothecin derivative conjugates |
| JP2025519421A (ja) * | 2022-06-09 | 2025-06-26 | ベイジーン スイッツァランド ゲーエムベーハー | 抗体薬物複合体 |
| US20230408497A1 (en) * | 2022-06-20 | 2023-12-21 | Sysmex Corporation | Labeled polypeptide, modified polypeptide, production method for these polypeptides, reagent containing these polypeptides, and measurement method for target substance |
| WO2024012536A1 (zh) * | 2022-07-14 | 2024-01-18 | 百奥泰生物制药股份有限公司 | 抗Nectin-4抗体、其抗体药物偶联物及应用 |
| CN117982672A (zh) * | 2022-07-14 | 2024-05-07 | 百奥泰生物制药股份有限公司 | 抗Nectin-4抗体药物偶联物及应用 |
| EP4309676A1 (en) * | 2022-07-22 | 2024-01-24 | Emergence Therapeutics AG | Novel anti-nectin-4 antibody camptothecin derivative conjugates |
| WO2024028258A1 (en) * | 2022-08-01 | 2024-02-08 | Philochem Ag | Conjugates of psma-binding moieties with cytotoxic agents |
| EP4324849A1 (en) * | 2022-08-18 | 2024-02-21 | Emergence Therapeutics AG | Humanized anti-nectin-4 antibodies |
| EP4344707A1 (en) * | 2022-09-29 | 2024-04-03 | Emergence Therapeutics AG | New anti-nectin-4 antibody drug conjugates |
| KR20250079213A (ko) | 2022-10-09 | 2025-06-04 | 라노바 메디신즈 리미티드 | 화합물, 조성물 및 방법 |
| KR20250079227A (ko) * | 2022-10-25 | 2025-06-04 | 머크 샤프 앤드 돔 엘엘씨 | 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도 |
| IL320634A (en) * | 2022-11-04 | 2025-07-01 | Alx Oncology Inc | EXATECAN derivatives and antibody-drug conjugates |
| WO2024102523A1 (en) * | 2022-11-09 | 2024-05-16 | Obi Pharma, Inc. | Glycosynthase variants for antibody-drug conjugate engineering |
| WO2024191598A1 (en) * | 2023-03-10 | 2024-09-19 | Emory University | Labeled amplifier oligonucleotides for detecting low or ultra low expression of cancer markers and uses in managing cancer treatments |
| CN118666946A (zh) * | 2023-03-15 | 2024-09-20 | 上海亲合力生物医药科技股份有限公司 | 连接子及使用其的偶联药物、抗体偶联药物及其应用 |
| CN118852442A (zh) | 2023-04-26 | 2024-10-29 | 上海麦科思生物医药有限公司 | 抗ptk7抗体及其用途 |
| AU2024304180A1 (en) * | 2023-06-13 | 2026-01-08 | Adcentrx Therapeutics, Inc. | Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins |
| JP7689606B2 (ja) * | 2023-06-20 | 2025-06-06 | イーライ リリー アンド カンパニー | ネクチン－４抗体及び抗体－薬物コンジュゲート |
| EP4735047A1 (en) * | 2023-06-28 | 2026-05-06 | Université de Tours | Pegylated linkers and uses thereof |
| KR20260085122A (ko) | 2023-09-29 | 2026-06-08 | 악티스 온콜로지, 인크. | 미니단백질, 접합체 및 이의 용도 |
| EP4534101A1 (en) | 2023-10-02 | 2025-04-09 | Eli Lilly and Company | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload |
| EP4534102A1 (en) | 2023-10-02 | 2025-04-09 | Eli Lilly and Company | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload |
| KR20260094408A (ko) * | 2023-10-13 | 2026-06-22 | 주식회사 리가켐바이오사이언스 | 토포이소머라아제 i 저해제를 포함하는 항-클라우딘 18.2 항체-약물 접합체 및 이의 용도 |
| WO2025083067A1 (en) * | 2023-10-17 | 2025-04-24 | Adc Therapeutics Sa | Anti-claudin-6 conjugates |
| FR3155709A1 (fr) * | 2023-11-27 | 2025-05-30 | Skymab Biotherapeutics | Conjugue anticorps-medicament et ses utilisations |
| FR3155708A1 (fr) * | 2023-11-27 | 2025-05-30 | Skymab Biotherapeutics | Conjugue anticorps-medicament et ses utilisations |
| US20250186604A1 (en) * | 2023-12-06 | 2025-06-12 | Adc Therapeutics Sa | Anti-psma antibody conjugates |
| WO2025153092A1 (en) * | 2024-01-18 | 2025-07-24 | Beijing Joinn Biologics Co., Ltd | Antibody-drug conjugate |
| WO2025209545A1 (zh) * | 2024-04-03 | 2025-10-09 | 上海药明合联生物技术有限公司 | 用于抗体药物偶联物的连接子、其用途和由其制备的抗体药物偶联物 |
| FR3164899A1 (fr) * | 2024-07-24 | 2026-01-30 | Skymab Biotherapeutics | Conjugue anticorps-medicament et ses utilisations |
| EP4732850A1 (en) * | 2024-10-25 | 2026-04-29 | Antelope Therapeutics SAS | Antibody-drug conjugates and their uses |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| WO1999061061A1 (fr) * | 1998-05-22 | 1999-12-02 | Daiichi Pharmaceutical Co., Ltd. | Composites medicamenteux |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US7375234B2 (en) | 2002-05-30 | 2008-05-20 | The Scripps Research Institute | Copper-catalysed ligation of azides and acetylenes |
| WO2004043493A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| US7807619B2 (en) | 2004-11-01 | 2010-10-05 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
| EP2907525B1 (en) | 2007-11-21 | 2018-05-16 | University Of Georgia Research Foundation, Inc. | Dibenzocyclooctene-compounds for bioorthogonal reactions |
| US20110301056A1 (en) | 2008-12-12 | 2011-12-08 | Oncotherapy Science, Inc. | Nectin-4 for target genes of cancer therapy and diagnosis |
| WO2011121453A2 (en) | 2010-03-30 | 2011-10-06 | Clavis Pharma Asa | Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate |
| ES2874306T3 (es) * | 2010-09-29 | 2021-11-04 | Agensys Inc | Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12 |
| CA2858806A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
| WO2014202773A1 (en) | 2013-06-20 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
| PT3057585T (pt) | 2013-10-15 | 2020-10-21 | Seagen Inc | Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando |
| EP3733209A1 (en) | 2014-10-03 | 2020-11-04 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
| ES2885854T3 (es) | 2014-10-14 | 2021-12-15 | Polytherics Ltd | Proceso para la conjugación de un péptido o proteína con un reactivo que comprende un grupo saliente que incluye una porción de PEG |
| EP3347048B1 (en) | 2015-09-09 | 2020-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to nectin-4 and uses thereof |
| EP3546448B1 (en) | 2016-11-25 | 2022-04-06 | Mabwell (Shanghai) Bioscience Co., Ltd. | Di-substituted maleic amide linker for antibody-drug conjugating and preparation method and use thereof |
| US11274160B2 (en) | 2017-03-02 | 2022-03-15 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to Nectin-4 and uses thereof |
| TWI870338B (zh) | 2017-06-05 | 2025-01-21 | 美商艾澤西公司 | 粘附分子-4結合蛋白及其使用方法 |
| KR20260011205A (ko) | 2017-10-05 | 2026-01-22 | 소니그룹주식회사 | 프로그램가능한 중합체성 약물 |
| EP3700577A1 (en) | 2017-10-23 | 2020-09-02 | Mablink Bioscience | Ligand-drug-conjugate comprising a single molecular weight polysarcosine |
| TWI920652B (zh) | 2018-06-07 | 2026-04-01 | 美商思進公司 | 喜樹鹼結合物 |
| UA130338C2 (uk) | 2018-09-26 | 2026-01-28 | Джянгсу Хенгруй Медісін Ко., Лтд. | Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування |
| JP7408646B2 (ja) | 2018-09-30 | 2024-01-05 | ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド | 抗－ｂ７ｈ３抗体－エキサテカンアナログコンジュゲート及びその医薬用途 |
| CN113613679A (zh) | 2019-03-19 | 2021-11-05 | 保罗·谢勒学院 | 基于甘氨酸的接头的转谷氨酰胺酶缀合方法 |
| RS64961B1 (sr) * | 2019-04-26 | 2024-01-31 | Immunogen Inc | Derivati kamptotecina |
| CA3085001C (en) | 2019-05-20 | 2021-10-05 | Mabplex International, Ltd. | One-pot process for preparing intermediate of antibody-drug conjugate |
| AU2020364959B2 (en) | 2019-10-07 | 2026-07-09 | Centre National De La Recherche Scientifique - Cnrs - | Antibodies having specificity for Nectin-4 and uses thereof |
| US20230025600A1 (en) | 2019-11-25 | 2023-01-26 | Agensys, Inc. | Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins |
| CN114845740B (zh) * | 2020-01-31 | 2026-06-02 | 先天制药公司 | 癌症的治疗 |
| CN113527486B (zh) | 2020-04-21 | 2025-12-02 | 迈威(上海)生物科技股份有限公司 | 一种抗Nectin-4的抗体及其应用 |
| IL298903A (en) | 2020-06-18 | 2023-02-01 | Bioatla Llc | Antibodies against nectin-4 are conditionally active |
| KR20230060509A (ko) | 2020-09-04 | 2023-05-04 | 노바록 바이오테라퓨틱스 리미티드 | 넥틴-4 항체 및 이의 용도 |
| JP7904824B2 (ja) | 2020-09-15 | 2026-08-13 | シンアフィックス ビー．ブイ． | 抗体－エクサテカンコンジュゲート |
| JP2024501121A (ja) | 2020-11-25 | 2024-01-11 | イナート・ファルマ・ソシエテ・アノニム | 癌の処置 |
| WO2023227660A1 (en) | 2022-05-25 | 2023-11-30 | Innate Pharma | Nectin-4 binding agents |
-
2021
- 2021-01-28 CN CN202180007603.2A patent/CN114845740B/zh active Active
- 2021-01-28 DK DK21702624.4T patent/DK4096717T3/da active
- 2021-01-28 ES ES21702624T patent/ES3014740T3/es active Active
- 2021-01-28 EP EP21702624.4A patent/EP4096717B1/en active Active
- 2021-01-28 WO PCT/EP2021/051938 patent/WO2021151984A1/en not_active Ceased
- 2021-01-28 US US17/796,707 patent/US12594343B2/en active Active
- 2021-01-28 AU AU2021213421A patent/AU2021213421B2/en active Active
- 2021-01-28 CA CA3160557A patent/CA3160557A1/en active Pending
- 2021-01-28 EP EP24211980.8A patent/EP4512478A3/en active Pending
- 2021-01-28 JP JP2022546059A patent/JP7682553B2/ja active Active
-
2025
- 2025-04-14 AU AU2025202617A patent/AU2025202617A1/en active Pending
- 2025-05-07 JP JP2025077110A patent/JP2025121970A/ja active Pending
-
2026
- 2026-01-15 US US19/449,656 patent/US20260199511A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114845740A (zh) | 2022-08-02 |
| US12594343B2 (en) | 2026-04-07 |
| AU2021213421A1 (en) | 2022-06-23 |
| EP4096717A1 (en) | 2022-12-07 |
| ES3014740T3 (en) | 2025-04-24 |
| US20260199511A1 (en) | 2026-07-16 |
| AU2025202617A1 (en) | 2025-05-15 |
| WO2021151984A1 (en) | 2021-08-05 |
| EP4096717B1 (en) | 2024-12-11 |
| AU2021213421B2 (en) | 2025-02-06 |
| JP2023512036A (ja) | 2023-03-23 |
| JP2025121970A (ja) | 2025-08-20 |
| CN114845740B (zh) | 2026-06-02 |
| JP7682553B2 (ja) | 2025-05-26 |
| US20230099149A1 (en) | 2023-03-30 |
| EP4512478A3 (en) | 2025-05-21 |
| CA3160557A1 (en) | 2021-08-05 |
| EP4512478A2 (en) | 2025-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3986897T1 (sl) | Inhibitor EGFR za zdravljenje raka | |
| IL285771A (en) | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator | |
| DK3431105T3 (da) | Medicinsk sammensætning til behandling af cancer | |
| DK3582853T3 (da) | Cykliske dinukleotidforbindelser til behandling af cancer | |
| DK3458052T3 (da) | Kombinationsbehandling af cancer | |
| DK3525774T3 (da) | Lasofoxifen behandling af er+ brystcancer | |
| IL291170A (en) | Treatment of hr deficient cancer | |
| EP4222352A4 (en) | BOLTER | |
| DK3518932T3 (da) | Behandling af prostatacancer | |
| DK3768830T5 (da) | Cancerterapi | |
| IL281845A (en) | Combination therapy for the treatment of cancer | |
| IL281600A (en) | Methods of treating cancer | |
| DK3576740T3 (da) | Cancerbehandling | |
| EP4493175A4 (en) | MIRDAMETINIB TREATMENT | |
| DK4225297T3 (da) | Kombinationsbehandling til behandling af cancer | |
| EP3576791A4 (en) | CALRETICULIN-MEDIATION CANCER TREATMENT | |
| IL308399A (en) | Methods of treating cancer | |
| EP4178042A4 (en) | CONNECTOR | |
| EP4102649A4 (en) | CONNECTOR | |
| MA54932A (fr) | Traitement contre le cancer | |
| EP4025203A4 (en) | CANCER TREATMENT | |
| EP4401721A4 (en) | CANCER TREATMENT | |
| IL281281A (en) | Combination therapy for the treatment of prostate cancer | |
| IL280968A (en) | Combination therapy | |
| IL325421A (en) | Combinational treatment |